Malte Peters has been appointed chief development officer at MorphoSys AG, succeeding Arndt Schottelius, and will oversee the company’s clinical and preclinical antibody therapeutic programmes. The appointment takes effect on 1 March.
Dr Peters joins from the Novartis generics unit Sandoz where he has been global head of clinical development for biopharmaceuticals. He has also been medical director at Micromet AG, now part of Amgen Inc, and was head of translational research and pharmacogenomics at Merck KGaA.
MorphoSys announced the appointment on 5 January 2017.
Copyright 2017 Evernow Publishing Ltd